Children's Hospital Colorado Anschutz Medical Campus
Aurora13123 East 16th Ave Aurora, CO 80045
Clinical Interest for Patients
My clinical focus is in the treatment of children with cancer, in particular leukemias and conditions that may lead to leukemias such as inherited bone marrow failure syndromes or myelodysplastic syndromes (MDS).
I believe in providing the most evidence-based and compassionate care possible to my patients and their families. A diagnosis of cancer is one of the worst experiences of a family's life, and making it easier or more manageable to the child and his/her family in some small way is as important to me as providing physical healing. I and my colleagues also strive to treat patients with the most up-to-date in cancer therapies available.
- Pediatric Hematology / Oncology ( 2019 )
Conditions & Treatments
Aplastic Anemia, Chemotherapy, Leukemia (Childhood), Lymphoma, Myelodysplastic Syndrome, Pediatric Cancer
Interests & Activities
In addition to clinical care of patients, which is most important to me, I am interested in research that brings newer and better drugs into the care of children with cancer. I am also passionate about medical education.
Education & Training
MD, Tulane University School of Medicine (2011)
BS, University of Southern Mississippi (MS) (2004)
PhD, Tulane University School of Medicine (2011)
Cincinnati Children's Hospital Medical Center Program (2012)
Cincinnati Children's Hospital Medical Center Program (2014)
University of Colorado (Children's Hospital Colorado) Program (2017)
American Academy of Pediatrics, Member
American Board of Pediatrics, Board-Certified, General Pediatrics
American Society of Hematology, Member
American Society of Pediatric Hematology/Oncology, Member
Research & Grants
Young Investigator Award (2018)
Translational Research Program Grant (2019)
NIH Loan Repayment Program Grant (2020)
Morgan Adams Foundation Research Grant (2020)
Clinician Scientist Development Grant (2022)
Research Interests for Patients
I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.